Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for ...
ISLAMABAD: The State-Owned Enterprises (SOEs) incurred net loss of Rs 122.9 billion in FY 2024-25 as compared to ...
COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones.
Friends of Commerce reflects on 2025 - a year defined by expanded global delivery, deepened strategic partnerships, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback